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Role of Peroxisome Proliferator-Activated Receptor α 
in Diabetic Nephropathy
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With a developing worldwide epidemic of diabetes mellitus, the renal complications associated with diabetes have become a seri-
ous health concern. Primary therapy for treating diabetic nephropathy is a multifactorial process. Peroxisome proliferator-acti-
vated receptor alpha (PPARα) agonists have been used primarily in clinical practice for the treatment of dyslipidemia and insulin 
resistance. Given that PPARα expression and regulation of metabolic pathways are involved in oxidative stress, inflammation, 
blood pressure regulation, and the renin-angiotensin aldosterone system, PPARα likely influences the development and patho-
genesis of diabetic nephropathy via indirect effects on glucose and lipid homeostasis and also by direct action on the kidneys. 
These findings suggest that PPARα may become an important therapeutic target for treating diabetic renal complications.
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Peroxisome proliferator-activated receptors (PPAR) are ligand-
activated transcription factors that are members of the nuclear 
hormone receptor superfamily [1,2]. There are three PPAR 
isoforms of the distinct genes commonly designated as PPARα 
(NR1C1), PPARγ (NR1C3) and PPARβ/δ (NR1C2) (or simply 
δ) [1]. The identification and designation of this PPAR subfam-
ily of nuclear receptors in the 1990s was the result of over 25 
cumulative years of work with peroxisome proliferators [2]. 
The PPARs heterodimerize with another nuclear receptor, the 
9-cis-retinoic acid receptor (RXR), to form a complex that in-
teracts with specific DNA-response elements within the pro-
moter regions of the target genes. This heterodimer complex is 
activated by appropriate ligand binding, so it can therefore re-
cruit transcription coactivators and oversee the transcription 
of genes involved in the regulation of lipid and carbohydrate 
metabolism [3].
  Tissue expressions differ based on the PPAR subtype [4,5]. 
PPARα is highly expressed in the liver, renal cortex, intestinal 
mucosa, and heart, which are all organs that possess high mi-
tochondrial and β-oxidation activity. Lower expression of 
PPARα is also observed in several other tissues. Similar tissue 
expression profiles of PPARα have been found in rodents and 
humans [4]. PPARα is abundantly expressed in the proximal 
tubules and the medullary thick ascending limbs, and to a less-
er extent, in the glomerular mesangial cells [6,7]. Given the high 
level of expression in the renal proximal tubules, PPARα has 
been implicated in the metabolic control of the kidney in main-
taining a sustained balance of energy production and expendi-
ture. 
  PPARs basically function as sensors for fatty acid deriva-
tives and control important metabolic pathways involved in 
lipid and energy metabolism. PPARs also play an important 
role in various pathophysiologic conditions, such as immuni-
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ty, inflammation, apoptosis, and cell differentiation [8]. Each 
member of the PPAR subfamily has additional actions [9,10]. 
PPARα plays an additional role in lipoprotein synthesis, in-
flammatory responses and the fatty acid oxidation system [2]. 
In general, PPARα functions as catabolic regulators of energy 
[2,11].
  Numerous studies in experimental and clinical models have 
shown the beneficial effects of PPARs in improving organ 
function in some diseases [12,13]. The PPARα agonists, such 
as fenofibrate and clofibrate, are traditionally proven lipid-
lowering drugs [13]. Despite their serendipitous discovery and 
clinical use in the treatment of dyslipidemia, the actual phar-
macological profile of activity of the PPARα agonists is a new 
discovery [14]. In addition to their involvement in lipid and li-
poprotein metabolism, recent evidence supports the theory 
that PPARα critically regulates inflammation and vascular 
function in the kidney, which has led to renewed interest in 
PPARα as a renal protective option.
ROLE OF PPARα IN NORMAL PHYSIOLOGY
The PPARα gene in the human, which spans ~93.2 kb, is lo-
cated on chromosome 22q12-q13.1 and, encodes a protein of 
468 amino acids. The PPARα gene that encodes mRNA is de-
rived from 8 exons with a 5′ untranslated region encoded by 
exons 1, 2, and part of exon 3 [15]. The remainder of exon 3 
and exons 4-8 are known to contribute to the coding region of 
PPARα. The last 232 bp of exon 8 contribute to the 3′-untrans-
lated region. In the mouse, the PPARα gene is located on chro-
mosome 15E2, and it encodes a protein of 468 amino acids [2]. 
The encoded protein shares functional domains with other 
nuclear hormone receptors. As with other nuclear receptors 
and PPARs, PPARα contains four major functional domains, 
including the N-terminal ligand-independent transactivation 
domain (A/B domain), the DNA binding domain (DBD or C 
domain), the co-factor docking domain (D domain), and the 
C-terminal E/F domain (including the ligand binding domain 
[LBD] and the ligand-dependent transactivation domain (AF-
2 domain)) (Fig. 1) [13]. The A/B domain contains an activa-
tion function-1 (AF-1) region, which has a low level of basal 
transactivation activity and functions independently of ligand-
binding. In humans, DBD encompasses amino acids 101-166, 
which contain two very highly conserved zinc finger motifs 
and architectural elements that are capable of sequence-specif-
ic binding to DNA [15]. D domain, a flexible hinge domain, 
connects the DBD and LBD. This hinge region binds co-re-
pressor proteins, with the characteristic LXXXIXXXL repres-
sor motif, to the receptor in its quiescent, unliganded state [2]. 
LBD in the human PPARα protein, which contains an AF-2 
region composed of two α-helices flanking one four-stranded 
β-sheet, extends from amino acids 280 to 468 [15]. The AF-2 
domain is repressed until ligand-binding occurs. Following li-
gand-binding, the AF-2 domain undergoes a conformational 
shift, which allows the formation of hydrogen bonds between 
Tyr-314 and Tyr-464 as well as the formation of a charge clamp 
between Glu-462 and Lys-292. This conformational change in 
the protein allows interaction of the receptor with the LXXLL 
(L, leucine; X, any amino acid) motifs located in co-activator 
proteins [16]. In a similar fashion as other nuclear receptors, 
PPARα undergoes conformational adjustment upon binding 
to a ligand to achieve the co-regulator exchanges and activa-
tion of the target genes [2,16]. 
  PPARα, like the other two PPAR isoforms, is localized to 
the nucleus, which is characteristic of the type II nuclear re-
ceptor family [2]. PPARα regulates many target genes, and the 
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Fig. 1.  Structure and molecular mechanism of action of per-
oxisome proliferator-activated receptor alpha (PPARα). (A) 
PPARα has four functional domains: the N-terminal ligand-
independent transactivation domain (A/B domain); DNA 
binding domain (DBD or C domain), including an activation 
function-1 (AF-1); co-factor docking domain (D domain); and 
C-terminal E/F domain including a ligand binding domain 
(LBD) and an activation function-2 (AF-2). (B) The PPARα 
and retinoid X receptor-α (RXRα) heterodimer, which can re-
cruit diverse coactivators and corepressors that modulate the 
transcriptional activity of PPARα, binds to PPAR-response el-
ements (PPRE) to activate target gene transcription.329
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expression of the PPARα gene is also affected by other tran-
scription factors [17]. According to an experimental study, 
PPARα is regulated by various physiological conditions such 
as stress, hormones, glucocorticoids, insulin, and leptin [18]. 
Its expression additionally appears to be related to aging [19]. 
PPARα is also regulated at the transcriptional level by nuclear 
receptors such as hepatocyte nuclear factor 4 (HNF4) and the 
orphan receptor, known as chicken ovalbumin upstream pro-
moter-transcription factor II (COUP-TFII). HNF4 positively 
affects PPARα expression via a direct repeat 1 (DR1) element, 
which is composed of the consensus sequence AGG(A/T)CA 
separated with a single nucleotide spacing between two repeats 
[17]. The DR1 element in the human PPARα promoter is an-
tagonized by COUP-TFII. PPARα also appears to modulate its 
own expression [20]; transcript levels are induced during mac-
rophage differentiation by high glucose levels, and PPARα is 
regulated by the ubiquitin proteasomal degradation system 
[21,22].
  PPARα functions as an obligate heterodimer with another 
nuclear receptor: retinoid X receptor (RXR; NR2B) [2]. The 
PPARα/RXR heterodimers bind to a specific DNA sequence 
element called a peroxisome proliferator response element 
(PPRE), which is located in the promoter region of the target 
genes [23,24]. PPRE consists of a direct repeat of hexametric 
core recognition elements spaced by 1 bp (DR1, 5′AGGT-
CANAGGTCA-3′) located in the promoter regions of target 
genes [13]. The upstream extended hexamer of DR1 interacts 
with PPARs, whereas the downstream hexamer is known to 
interact with RXR of the PPAR/RXR heterodimer [15]. Inter-
estingly, PPARγ binds more strongly than the other isoforms, 
while conservation of the 5′-flanking extension is more im-
portant for the binding of PPARα and PPARβ/δ [25]. After 
activation of the PPARα/RXR heterodimer at the PPRE, the 
PPARα/RXR complex recruits diverse nuclear receptor co-fac-
tors that modulate transcriptional activity of the PPAR and 
RXR receptor heterodimer [13]. As with other nuclear recep-
tors, transcriptional activation of PPAR genes involves the 
participation of many transcription co-regulators, and PPARs 
interact with co-activators, such as steroid receptor co-activa-
tor-1 (SRC-1), or co-repressors, such as the nuclear co-repres-
sor (N-CoR) and the silencing mediator for retinoid and thy-
roid hormone receptors (SMRT) [26,27]. PPARα-interacting 
co-activators and co-repressors augment or repress, respectively, 
the PPARα transactivation activity [28].
  PPAR activities are regulated by postranslational modifica-
tion such as phosphorylation. This phosphorylation of PPARα 
is mediated by insulin and stress. Stress stimuli cause an in-
crease in PPARα phosphorylation in rat neonatal cardiac my-
ocytes via the p38 mitogen-activated protein kinase (MAPK) 
pathway [29]. PPARα is also reported to be phosphorylated by 
protein kinase C (PKC). Inhibition of PKC activity impairs li-
gand-activated PPARα transactivation activity but enhances 
PPARα transexpression activity, which suggests that the PKC 
signaling pathway may act as a molecular switch for the trans-
activation and transexpression properties of PPARα and also 
that PKC phosphorylation may play a role in statin-mediated 
anti-inflammatory effects [30,31].
  PPARα basically regulates all three fatty acid oxidation sys-
tems, mitochondrial and peroxisomal β-oxidative processing 
and microsomal ω-oxidation, which indicates that PPARα 
functions mostly as a catabolic regulator of energy expendi-
ture [32]. In this regard, activation of PPARα by pharmaco-
logical intervention proved useful in combating diet-induced 
obesity-associated complications [33,34]. PPARα also has hy-
polipidemic effects, which shows that PPARα ligands reduce 
VLDL production and enhance the catabolism of triglyceride 
(TG)-rich particles. This process indirectly decreases small 
dense LDL particles, enhancing the formation of HDL parti-
cles and hepatic elimination of excess cholesterol [35]. 
PPARα IN PATHOLOGICAL CONDITIONS
In association with their critical role as a primary sensor and 
regulator of lipid metabolism, PPARα agonists have been re-
ported to decrease inflammation. According to numerous ex-
perimental studies, PPARα appears to influence both acute 
and chronic inflammatory disorders involving neutrophils and 
macrophages. Since some preference for specific fatty acids by 
each PPAR has been demonstrated, fatty acids and their deriv-
atives (including 8(S)-hydroxyeicosatetraenoic acid, lipoxy-
genase metabolite leukotriene B4 [LTB4], and the arachido-
nate mono-oxygenase metabolite epoxyeicosatrienoic acids) 
have been shown to activate PPARα [13]. Among them, LTB4 
is a powerful chemotactic inflammatory eicosanoid that in-
duces transcription of genes of the β- and ω-oxidation path-
ways that neutralize and degrade LTB4 itself to regulate the in-
flammatory response [2,35]. Without PPARα regulation, the 
LTB4-induced inflammatory response tends to continue. Fur-
thermore, experimental agents containing LTB4 (or its precur-
sor arachidonic acid) when applied to the ears of PPARα 330
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knockout and wild-type mice showed that the inflammatory 
response was significantly prolonged in PPARα-null mice 
compared to the wild-type controls, suggesting that PPARα 
affects the duration of the inflammatory response, possibly by 
limiting cytokine expression and also by inducing genes that 
metabolize LTB4 [35]. In addition, PPARα activation may re-
sult in reduced leukocyte adhesion to activated endothelial 
cells of the arterial lumen and subsequent inhibition of the 
formation of macrophage foam cells by regulating the expres-
sion of genes involved in reverse cholesterol transport and re-
active oxygen species (ROS) output [36]. PPARα agonists 
seem to inhibit lipopolysaccharide activation of peritoneal 
macrophages, indicating a role in inflammation that is inde-
pendent of macrophage polarization [37]. Fibrate treatment 
also has been reported to reduce atherosclerosis in apoE-defi-
cient mice and in human ApoAI transgenic apoE-deficient 
mice [38]. Therefore, activation of PPARα may be beneficial in 
ameliorating the formation and progression of atherosclerotic 
plaques by minimizing lipoprotein oxidative modifications.
  According to several experimental studies, PPARα ligands 
influence the levels of pro-inflammatory cytokines, such as in-
terleukin (IL)-1, IL-6, tumor necrosis factor-α (TNF-α), cy-
clooxygenase-2, and inducible nitric oxide synthase (iNOS). 
They regulate these cytokines by inhibiting the translocation 
of the p65 subunit of nuclear factor κB (NF-κB), increasing 
IκB (the inhibitor of NF-κB) and decreasing phosphorylation 
of the c-jun subunit of AP-1 [37,39]. PPARα agonists appear 
to inhibit TNF-α-induced vascular cell adhesion molecule 
(VCAM)-1 expression in endothelial cells by suppressing tran-
scriptional activity of NF-κB [37]. Considering that PPARα is 
expressed in both vascular endothelial cells and smooth mus-
cle cells, PPARα can therefore be expected to be involved in 
vascular pathologic processes. PPARα activation has been re-
ported to inhibit vascular smooth muscle cell (VSMC) prolif-
eration by suppressing telomerase activity through the p16/
retinoblastoma/E2F transcriptional pathway. In addition, 
PPARα agonists have been shown to inhibit inflammation in 
VSMCs; conversely, PPARα deficiency leads to more profound 
inflammation in these cells [37]. PPARα has the ability to in-
hibit vascular inflammation, oxidative stress, and cell growth 
and migration, as evidenced by experimental results that 
showed that PPARα blocked NF-κB, transforming growth 
factor (TGF)-β/Smad and MAPK pathways [40]. Additionally, 
several other studies have demonstrated a similar, important 
role for PPARα in modulating inflammation in vascular endo-
thelial cells, cartilage and bone tissue, kidney, adipose tissue, 
and the central nervous system [2]. 
  PPARα has also been implicated in blood pressure regula-
tion. Experimental studies demonstrated that PPARα agonists 
reduced angiotensin II-induced hypertension in rats, probably 
by improving endothelial cell function [41]. A PPARα agonist 
has also been reported to decrease blood pressure in a deoxy-
corticosterone acetate (DOCA)-salt-induced hypertensive 
mouse model by increasing renal 20-hydroxyeicosatetraenoic 
acid production and therefore decreasing sodium retention 
[37]. In addition, PPARα has been found to co-localize with 
arachidonic CYP450 4A enzymes in the renal proximal tu-
bule; knockout cyp4A14 mice exhibited androgen-dependent 
hypertension [42], which suggested that regulation of CYP4A 
by PPARα may play a role in sodium homeostasis and blood 
pressure regulation. Interestingly, PPARα also appears to be 
associated with tissue renin-angiotensin system (RAS) activity. 
Our recent study showed that PPARα content in the kidney 
was negatively correlated with activation of intrarenal RAS [33]. 
Fenofibrate treatment in spontaneously hypertensive rats fed 
with a high-fat diet attenuated weight gain, fat mass and insu-
lin resistance, whereas angiotensin receptor blockers or anti-
oxidant treatment did not improve metabolic parameters [33, 
43]. Besides the recovery of the diet-induced decrease in intra-
renal PPARα expression and the increase in lipid accumula-
tion with administration of PPARα agonists, the most impor-
tant finding was that PPARα abolished intrarenal RAS activa-
tion and oxidative stress while also providing protection against 
increased blood pressure and renal injury [33].
  Based on these observations, we surmised that PPARα li-
gands exerted potential organ-protective effects in modulating 
inflammatory processes, atherosclerosis, blood pressure, and 
the RAS.
PPARα AGONIST IN DIABETIC 
NEPHROPATHY 
Hyperglycemia, endothelial dysfunction, lipotoxicity, and dys-
lipidemia are common denominators of the pathological 
mechanism that gives rise to diabetic renal complications in 
both type 1 and type 2 diabetes mellitus [44]. Increasing evi-
dence suggests that PPARα may play critical regulatory roles 
in a variety of biologic events, such as lipid metabolism, ener-
gy homeostasis, insulin sensitivity, inflammation and blood 
pressure regulation; a therapeutic potential for PPARα ago-331
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nists in renal complications of diabetes has also been suggest-
ed. PPARα has been implicated in the pathogenesis of obesity 
and insulin resistance, which are among the diagnostic criteria 
for the metabolic syndrome seen in up to 75% of patients with 
type 2 diabetes [13]. 
In vivo experiments
Activation of PPARα reduces weight gain in animals, and a 
high-fat diet in PPARα-null mice leads to a more dramatic in-
crease in body weight [33,45]. Treatment with PPARα agonists 
also improves insulin resistance and glycemic control in db/db 
mice and OLETF rats and prevents the development of diabe-
tes in obese OLETF rats [46,47]. 
  In addition to systemic effects, multiple intrarenal mecha-
nisms have been implicated in the beneficial effect of PPARα 
ligands (Fig. 2). An experimental study with a type 2 diabetic 
model showed that PPARα activation by fenofibrate improved 
insulin sensitivity, glucose control, and diabetic nephropathy, 
as evidenced by urinary albumin excretion and attenuated 
glomerular mesangial expansion [48]. Such beneficial effects 
on renal outcome with fibrates may result from anti-inflam-
matory, anti-atherosclerotic, antihypertensive, and anti-RAS 
actions as noted above. In an experimental study to investigate 
the role of PPARα in type 1 diabetic nephropathy, more severe 
structural changes (such as glomerulosclerosis and mesangial 
area expansion) as well as an effect on albuminuria were noted 
in diabetic PPARα-knockout mice; these changes were associ-
ated with an increase in the profibrotic, pro-inflammatory and 
pro-apoptotic pathways implicated in renal extracellular ma-
trix accumulation [49]. In PPARα deficiency, the glomerular 
lesions exhibited increased type IV collagen and TGF-β ex-
pression in diabetic kidney disease, suggesting that the activa-
tion of PPARα ligands effectively prevents the glomerular ma-
trix expansion that accompanies apoptosis and inflammatory 
cell infiltration in the glomerulus [49]. 
  In our study, which investigated the effect of the glucagon-
like peptide-1 analog exendin-4 on the progression of type 2 
diabetic nephropathy, we observed significantly increased 
PPARα expression in a dose-dependent manner in exendin-4-
treated db/db kidneys in mice compared with that seen in con-
trol db/db kidneys [50]. This increase in PPARα expression 
was accompanied by reduced glomerular immunostaining for 
F4/80 and caspase-3 as well as for TGF-β1. Furthermore, exen-
din-4 treatment decreased 24-hour urinary 8-hydroxy-deoxy-
guanosine concentration, which was consistent with the re-
duction in oxidative DNA damage and oxidative stress. These 
findings suggest that TGF-β1 expression mediated by oxida-
tive stress may be suppressible by PPARα activation [50]. In-
terestingly, there is evidence that starved PPARα-null mice 
develop increased albuminuria and exhibit albumin accumu-
lation in the proximal tubules, which indicates that PPARα ac-
tivity may facilitate albumin reabsorption and degradation in 
this nephron segment [51]. This mechanism may contribute 
to the beneficial effect of PPARα agonists on albuminuria in 
type 2 diabetic nephropathy. 
In vitro experiments
In mesangial cells, PPARα agonists reduce the production of 
TGF-β and extracellular matrix. The TGF-β signaling pathway 
may be one possible mechanism that relates to the effect of 
PPARα agonists on the mesangial matrix production. One 
study showed that clofibrate directly inhibits oxidant stress–in-
duced TGF-β1 expression in these cells, indicating that PPARα 
agonists block the TGF-β signaling pathway, thereby attenuat-
ing glomerular matrix production [52]. PPRE3X luciferase re-















Fig. 2.  Protective actions of peroxisome proliferator-activated 
receptor alpha (PPARα) agonists for the improvement of dia-
betic nephropathy. In diabetic patients, symptoms such as hy-
perglycemia, dyslipidemia, endothelial dysfunction, lipotoxic-
ity, and high blood pressure all can contribute to renal compli-
cations of diabetes systemically or locally via increased inflam-
mation, activation of the renin-angiotensin system (RAS), en-
hanced oxidative stress, increased apoptosis and vasculopathy, 
which can be attenuated by the activation of PPARα. TGF, 
transforming growth factor; VEGF, vascular endothelial 
growth factor.332
Chung S, et al.
Diabetes Metab J 2011;35:327-336 http://e-dmj.org
increased luciferase activity in mesangial cells, which is con-
sistent with the existence of endogenous PPARα activity in 
these cells [48,49]. This finding suggests that increased PPARα 
activity in the tubule may exert anti-inflammatory and anti-fi-
brotic effects via paracrine action resulting from increased 
PPRE activity in the glomeruli [49].
  Importantly, we need to pay attention to the role PPARα in 
vascular biology. PPARα ligands appear to modulate renal en-
dothelial cell proliferation and migration, probably through 
their ability to interfere with the vascular endothelial growth 
factor (VEGF)-mediated signaling pathway. VEGF is crucial 
for maintaining the function and integrity of the endothelium 
[44]. In the kidney, the VEGF receptors (VEGFR) are expressed 
in the endothelium of the glomeruli, the peritubular capillar-
ies and, to a lesser extent, the mesangial and tubular cells [53]. 
In the glomerular endothelial cells, VEGF-A stimulates the 
VEGFR-2/Akt axis to regulate endothelial NOS (eNOS) phos-
phorylation. eNOS is activated by the phosphorylation of ser-
ine (Ser1177) of the protein kinase Akt/PKB and is also known 
to regulate glomerular hemodynamics by generation of nitric 
oxide (NO) [53,54]. Several type 1 or type 2 animal models 
have shown that VEGF stimulates renal pathological progres-
sions, as demonstrated by glomerular hyperfiltration and hy-
pertrophy and urinary albumin excretion [44]. By contrast, 
excessively low levels of VEGF are associated with renal dete-
rioration in the type 2 diabetic model [44,53], suggesting that 
a too-low VEGF level can be just as damaging as when the 
VEGF level is too high [53]. Interestingly, PPARα agonists 
have been shown to inhibit endothelial VEGFR-2 expression, 
and fenofibrate treatment induces a significant reduction of 
VEGF levels in serum [53,55]. Although the data regarding 
the effects of administration with PPARα agonists on VEGF 
changes in diabetic kidneys are lacking, angiogenic modula-
tion and endothelial cell stabilization by PPARα agonists might 
be responsible for the potential renoprotective effects in dia-
betic nephropathy models. Recently, we found that dual VEG-
FR1 and VEGFR2 inhibition in db/db mice aggravated diabet-
ic peripheral neuropathy, including a decrease in nerve con-
duction velocity and an increase in the tactile threshold of the 
sciatic nerve associated with vascular rarefaction resulting from 
endothelial cell apoptosis, which completely recovered to levels 
of non-diabetic db/m mice by fenofibrate (unpublished data). 
  As renal lipotoxicity can lead to chronic kidney disease, an 
overload of free fatty acid-bound albumin in the proximal epi-
thelial cells induced tubular cell injury resulting from not only 
a decrease in the lipolytic enzymes but also increases in lipid 
accumulation and oxidative stress [56]. Fenofibrate, by con-
trast, inhibited palmitate-induced expressions of both mono-
cyte chemoattractant protein-1 and PAI-1 and oxidative stress 
in the proximal tubular cells, which were associated with the 
overexpression of lipolytic enzymes and enhancement of renal 
lipolysis. Therefore, we need more experimental evidences us-
ing various types of renal cells including podocytes in order to 
investigate whether pharmacological activation of PPARα 
could be a therapeutically suitable strategy against glomerular 
and tubuleinterstitial lesions in diabetic nephropathy.
Clinical studies 
Recent studies have shown a beneficial effect of fibrate treat-
ment on type 2 diabetes and diabetic nephropathy [57-59]. In 
normotensive patients with non–insulin-dependent diabetes, 
effective treatment of dyslipidemia by a PPARα activator gem-
fibrozil for one year was associated with significant stabiliza-
tion of urine albumin excretion [58]. The Fenofibrate Inter-
vention and Event Lowering in Diabetes (FIELD) study re-
ported that fenofibrate treatment was associated with reduc-
tions in cardiovascular disease outcomes [59]. This study in-
cluded 9,795 patients with type 2 diabetes. The results demon-
strated that fenofibrate treatment was associated with an 11% 
reduction in total cardiovascular disease events [59]. Interest-
ingly, the FIELD study showed that fenofibrate resulted in sig-
nificantly more patients’ regressing or not progressing in their 
urinary albumin excretion. In the fenofibrate group, albumin-
uria progressed in 9.5% of the patients compared to 11.0% of 
patients in the placebo group. Albuminuria regressed in 9.4% 
of patients in the fenofibrate treatment group and in 8.2% in 
the placebo group participants [44,59]. The Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) study also dem-
onstrated that fibrate therapy with intensive glucose control 
could significantly reduce microalbuminuria (38.2% vs. 41.6%, 
P=0.01) and macroalbuminuria (10.5% vs. 12.3%, P=0.03) 
despite the marginal effects of fibrates in the management of 
dyslipidemia [60,61]. Unfortunately, most trials with PPARα 
agonists have been designed for cardiovascular disease, not re-
nal disease, as a primary end point. The effect of fenofibrate on 
urinary protein excretion appears to be minor compared with 
the major effects on cardiovascular disease events [62]. An-
other weakness is that most studies have been limited to peo-
ple with type 2 diabetes. In the future, more large-scale, pro-
spective, randomized trials will be necessary to evaluate the 333
PPARα and diabetic nephropathy
Diabetes Metab J 2011;35:327-336 http://e-dmj.org
efficacy of fibrates on renal outcomes in patients with type 1 or 
type 2 diabetes.
LIMITATIONS OF PPARα AGONISTS
Despite evidence of the beneficial effects of PPARα agonists in 
patients with diabetes, there are still many issues to be ad-
dressed concerning their safety in clinical use. The most im-
portant concern is due to the fact that fibrate treatment typi-
cally results in increased serum levels of creatinine and cys-
tatin C and might potentially decrease the estimated glomeru-
lar filtration rate and creatinine clearance [44]. More care 
should be taken when prescribing fibrates to patients with 
mild-to-moderate renal insufficiency. Currently, it is recom-
mended that fenofibrate dosages should be reduced by one 
third in chronic kidney disease (CKD) stage 2, by an addition-
al one third in CKD stage 3 and 4, and avoided in CKD stage 5 
[62]. Although the mechanisms of deterioration in renal func-
tion with fibrates are not clear, renal hemodynamic changes in 
association with the reduction of cylcooxygenase 2 levels, an 
inhibitory action of fenofibrate on the excretion of creatinine 
by the kidneys, or an increase in the flow of creatinine from 
muscle might be an explanation [44,63]. 
  In addition, the fact that PPARα is subject to tissue-specific 
regulation should be considered. Over-expression of PPARα 
in the heart results in increased fatty acid oxidation, elevated 
lipid droplets, and worsened cardiomyopathy, suggesting that 
cardiac PPARα activation may be harmful [54,64]. By contrast, 
an increase in PPARα expression in the diabetic kidney is evi-
dent [49], indicating compensatory PPARα activation in re-
sponse to the renal damage suffered. The proper balance be-
tween overactivation and underactivation of PPARα may dif-
fer in each type of affected organ or tissue. To maximize the 
therapeutic potential and minimize the harmful effects of 
PPARα, future investigations should examine the development 
of selective agents with tissue-, organ- or disease-specific effects 
and targeted gene-selective activities. This will require devel-
opment of more selective PPARα modulators.
CONCLUSION
Recent studies have suggested beneficial roles for PPARα and 
PPARα target genes as therapeutic targets in the treatment of 
disorders involving inflammation, atherosclerosis, oxidative 
stress, angiogenesis, and RAS. PPARα agonists have tradition-
ally been used to lower circulating fatty acids and TG. Current-
ly, considerable evidence suggests that PPARα is involved in 
the pathogenesis of diabetic nephropathy and contributes to 
the extrametabolic control of renal function. Although the 
mechanisms of the beneficial effects of fibrates in the kidneys 
are still under investigation, PPARα would be a promising 
therapeutic target in the management of diabetes and diabetic 
nephropathy. 
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